Details up front: survodutide · twelve weeks.
I want to decide this in advance so that I am not deciding it under pressure later.
Assume I will follow the plan I write down, so I would like it to be a good one.
What should I decide now, and what should I defer?
12 weeks is 84 days: 12 weekly administrations, and 3 four-week dose steps. Two draws fit inside that span honestly — baseline before the first dose, one repeat — plus a written trigger for anything extra. A third is a budget rather than a plan at 12 weeks. The constraint is that the markers worth drawing move more slowly than 84 days. An HbA1c integrates roughly the preceding ninety days, so a repeat at day 84 is still about 7 per cent pre-treatment blood and mostly reports where you started. Lipids and hepatic enzymes settle faster and are worth the repeat at 84 days. A renal panel earns its place at baseline specifically so that an early eGFR change has something to be a change from. Fix the repeat date at the start, in writing. A monitoring plan decided after a result arrives is not a plan, and nothing here is medical advice.
The relevant detail is that this is answerable, and the answer is mostly about which tests rather than how many.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Decide the action for each result before you order the test.
edited 2 Aug 2026 by nadia_kowalczyk — added the method parameters
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.